On Apr. 27, 2005, results from two large NCI-sponsored randomized clinical trials showed that patients with early-stage, HER2-positive, invasive breast cancer who received the monoclonal antibody trastuzumab (Herceptin) in combination with chemotherapy experienced a significant decrease in their risk of cancer recurrence in comparison with patients who received the same chemotherapy without trastuzumab.